Numinus is an operating company at the forefront of the transformative change in addressing the growing prevalence of mental health issues and desire for greater wellness. Numinus is the first publicly traded company in Canada granted a license by Health Canada to conduct research into the production and extraction of psilocybin from mushrooms.
Stock Performance
Numinus News 106 articles
- Numinus faces TSX delisting, applies to list on the CSE
- Numinus refocuses on clinical-trial-site network and practitioner training in corporate update
- Numinus provides corporate update amid TSX delisting review and auditor turnover
- Numinus announces auditor change amid cease-trade order
- Numinus Approved as a State-Certified Natural Medicine Training Program in Colorado
- Numinus Wellness Inc. Announces CFO Transition
- Numinus Wellness Inc. Announces Strategic Wind-Down of Non-Operating Subsidiaries
- Numinus Wellness Announces Cease Trade Order and Provides Corporate Update
- Numinus Wellness Announces Corporate Update
- Numinus Provides Bi-Weekly Update on Annual Filings
- Numinus Wellness Closes Sale of Clinics and Launches Initiative to Increase Access to Mental Health Care
- Numinus Provides Bi-Weekly Update on Annual Filings
- Numinus Applies for Management Cease Trade Order
- Numinus Wellness Announces Sale of Clinics and Unique Data Partnership to Increase Access to Mental Health Care
- Numinus to Host Q3 Fiscal 2024 Results Conference Call on July 11, 2024
- Numinus Wellness Announces Resignation of Director
- Numinus Wellness Announces Strategic Acquisition of MedBright AI
- Numinus Wellness Comments on FDA Advisory Committee Meeting for Investigational MDMA-Assisted Therapy for PTSD
- Numinus Wellness Announces Voting Results From its Annual General Meeting of Shareholders
- Numinus and Cybin Embark on a Groundbreaking Journey: Pioneering Phase 3 Trials for Major Depressive Disorder
- Numinus Wellness Charts Path To Profitability While Strengthening Community Ties
- Numinus Wellness Receives Health Canada Approval for Study into Group Model for MDMA-Assisted Therapy
- Numinus Wellness Focused on Boosting Profitability and Expanding Community Support
- Cedar Clinical Research selected as clinical research site for Cybin’s Phase 3 Study of CYB003
- Numinus Wellness Provides Corporate Update
- Numinus to Host Q2 Fiscal 2024 Results Conference Call on April 15, 2024
- PharmAla Biotech Signs Sale Agreement with Numinus
- Numinus Wellness Submits Clinical Trial Application
- Numinus Wellness Provides Corporate Update
- Numinus Wellness Inc. Raises $6 Million
- Numinus Wellness Inc. Announces $6 Million Bought Deal Public Offering with Leads Orders from MAPS and Integrated V.C.
- Numinus Wellness Divests of Holdings in Co-Investment Feeder Fund 3
- Numinus Wellness Inc. Announces First Quarter Fiscal 2024 Results
- Cedar Clinical Research Selected as Clinical Research Site for Beckley Psytech’s Phase 2b Study
- Numinus Releases 2023 Financial Year Results— Finishing Strong
- Numinus Wellness Inc. Announces Fourth Quarter and Full Year Fiscal 2023 Results
- Numinus Announces Psychedelic Program for Mental Distress Associated with Chronic and Serious Illness through Cedar Clinical Research
- Numinus Wellness Inc. Announces At-The-Market Offering Equity Program
- Numinus Takes Actions to Accelerate its Path to Profitability by Focusing on Positive Cash Flow Generating Operations
- Psychedelic Drugs Market revenue to exceed USD 12 Billion by 2035, says Research Nester
Showing the 40 most recent of 106 articles.